This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

This study has been terminated.
(Study terminated early due to decision by sponsor)
Information provided by (Responsible Party):
Q-Med AB Identifier:
First received: December 12, 2012
Last updated: July 15, 2016
Last verified: July 2016
The purpose of the study is to determine whether a single intra-articular injection of Durolane is superior to a single injection of PBS for the relief of joint pain in patients with osteoarthritis of the knee.

Condition Intervention
Knee Osteoarthritis Device: Durolane Device: PBS

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane® Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee

Resource links provided by NLM:

Further study details as provided by Q-Med AB:

Primary Outcome Measures:
  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain score [ Time Frame: Up to 30 weeks ]

Secondary Outcome Measures:
  • Outcome Measures in Rheumatology Clinical Trials (OMERACT)-Osteoarthritis Research Society International (OARSI) Response [ Time Frame: Up to 30 weeks ]
  • WOMAC Physical Function score [ Time Frame: Up to 30 weeks ]
  • Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life questionnaire [ Time Frame: Up to 30 weeks ]
  • Physical Global Evaluation [ Time Frame: Up to 30 weeks ]
  • Patient Global Evaluation [ Time Frame: Up to 30 weeks ]

Enrollment: 75
Study Start Date: December 2012
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Durolane
Single intraarticular injection of Durolane
Device: Durolane
Placebo Comparator: PBS
Single intraarticular injection of PBS
Device: PBS


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body Mass Index (BMI) ≤ 35 kg/m2
  • Symptomatic OA of the knee
  • K L severity grade 1 or 2
  • If bilateral OA, contralateral knee K L severity grade 0 or 1

Exclusion Criteria:

  • Has clinically apparent tense effusion of the index knee
  • Has had surgery on the symptomatic knee within the previous 12 months or arthroscopy in the index knee in the past 3 months
  • Has any painful orthopedic disorders of the back or hip
  • Has a joint disorder other than osteoarthritis in the index knee
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01753830

  Show 25 Study Locations
Sponsors and Collaborators
Q-Med AB
Principal Investigator: Nebojsa Skrepnik, MD, PhD Tucson Orthopaedic Institute
  More Information

Responsible Party: Q-Med AB Identifier: NCT01753830     History of Changes
Other Study ID Numbers: 35GA1203
Study First Received: December 12, 2012
Last Updated: July 15, 2016

Keywords provided by Q-Med AB:
Intraarticular injection
Hyaluronic acid
Knee osteoarthritis

Additional relevant MeSH terms:
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on September 19, 2017